99 related articles for article (PubMed ID: 10188727)
1. A comparison of an anti-gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in SCID mice.
Watson SA; Michaeli D; Grimes S; Morris TM; Varro A; Clarke PA; Smith AM; Justin TA; Hardcastle JD
Int J Cancer; 1999 Apr; 81(2):248-54. PubMed ID: 10188727
[TBL] [Abstract][Full Text] [Related]
2. Antibodies raised by gastrimmune inhibit the spontaneous metastasis of a human colorectal tumour, AP5LV.
Watson SA; Michaeli D; Morris TM; Clarke P; Varro A; Griffin N; Smith A; Justin T; Hardcastle JD
Eur J Cancer; 1999 Aug; 35(8):1286-91. PubMed ID: 10615243
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth.
Watson SA; Morris TM; Varro A; Michaeli D; Smith AM
Gut; 1999 Dec; 45(6):812-7. PubMed ID: 10562577
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model.
Watson SA; Michael D; Justin TA; Grimes S; Morris TM; Robinson G; Clarke PA; Hardcastle JD
Int J Cancer; 1998 Mar; 75(6):873-7. PubMed ID: 9506532
[TBL] [Abstract][Full Text] [Related]
5. Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer.
Watson SA; Michaeli D; Grimes S; Morris TM; Robinson G; Varro A; Justin TA; Hardcastle JD
Cancer Res; 1996 Feb; 56(4):880-5. PubMed ID: 8631028
[TBL] [Abstract][Full Text] [Related]
6. Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumour AP5.
Watson SA; Michaeli D; Grimes S; Morris TM; Crosbee D; Wilkinson M; Robinson G; Robertson JF; Steele RJ; Hardcastle JD
Int J Cancer; 1995 Apr; 61(2):233-40. PubMed ID: 7705954
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer.
Smith AM; Justin T; Michaeli D; Watson SA
Clin Cancer Res; 2000 Dec; 6(12):4719-24. PubMed ID: 11156225
[TBL] [Abstract][Full Text] [Related]
8. Gastrimmune-induced antigastrin-17 antibodies inhibit acid secretion in a rat fistula model.
Smith AM; Morris T; Justin T; Michaeli D; Watson SA
Aliment Pharmacol Ther; 2001 Dec; 15(12):1981-8. PubMed ID: 11736730
[TBL] [Abstract][Full Text] [Related]
9. G17DT--a new weapon in the therapeutic armoury for gastrointestinal malignancy.
Watson SA; Gilliam AD
Expert Opin Biol Ther; 2001 Mar; 1(2):309-17. PubMed ID: 11727538
[TBL] [Abstract][Full Text] [Related]
10. Gastrin 17 vaccine--Aphton: Anti-gastrin 17 immunogen, G17DT.
BioDrugs; 2003; 17(3):223-5. PubMed ID: 12749761
[TBL] [Abstract][Full Text] [Related]
11. Anti-Gastrins Antiserum Combined with Lowered Dosage Cytotoxic Drugs to Inhibit the Growth of Human Gastric Cancer SGC7901 Cells in Nude Mice.
He Q; Gao H; Gao M; Qi S; Zhang Y; Wang J
J Cancer; 2015; 6(5):448-56. PubMed ID: 25874008
[TBL] [Abstract][Full Text] [Related]
12. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study.
Ajani JA; Hecht JR; Ho L; Baker J; Oortgiesen M; Eduljee A; Michaeli D
Cancer; 2006 May; 106(9):1908-16. PubMed ID: 16568451
[TBL] [Abstract][Full Text] [Related]
13. Antibodies raised against the extracellular tail of the CCKB/gastrin receptor inhibit gastrin-stimulated signalling.
McWilliams DF; Grimes S; Watson SA
Regul Pept; 2001 Jun; 99(2-3):157-61. PubMed ID: 11384777
[TBL] [Abstract][Full Text] [Related]
14. Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
Iwasa S; Goto M; Yasui H; Nishina T; Takahari D; Nakayama N; Taira K; Kusaba H; Fuse N; Hironaka S; Shimada Y; Nakajima TE
Jpn J Clin Oncol; 2012 Sep; 42(9):787-93. PubMed ID: 22782960
[TBL] [Abstract][Full Text] [Related]
15. Designing antibodies for the inhibition of gastrin activity in tumoral cell lines.
Barderas R; Shochat S; Timmerman P; Hollestelle MJ; MartÃnez-Torrecuadrada JL; Höppener JW; Altschuh D; Meloen R; Casal JI
Int J Cancer; 2008 May; 122(10):2351-9. PubMed ID: 18224686
[TBL] [Abstract][Full Text] [Related]
16. Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis.
Watson SA; Smith AM
Cancer Res; 2001 Jan; 61(2):625-31. PubMed ID: 11212260
[TBL] [Abstract][Full Text] [Related]
17. First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake.
Hara H; Kadowaki S; Asayama M; Ooki A; Yamada T; Yoshii T; Yamaguchi K
Int J Clin Oncol; 2018 Apr; 23(2):275-280. PubMed ID: 29039072
[TBL] [Abstract][Full Text] [Related]
18. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer.
Brett BT; Smith SC; Bouvier CV; Michaeli D; Hochhauser D; Davidson BR; Kurzawinski TR; Watkinson AF; Van Someren N; Pounder RE; Caplin ME
J Clin Oncol; 2002 Oct; 20(20):4225-31. PubMed ID: 12377966
[TBL] [Abstract][Full Text] [Related]
20. [Blocking the gastrin/cholecystokinin-B receptor autocrine loop influences the growth and apoptosis of human gastric cancer cells].
Wang WL; Zhou JJ; Zhou XC; Yang XF
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1989-92. PubMed ID: 17064598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
